There's a new way to screen for early detection of Alzheimer's disease. On Friday, the Food and Drug Administration (FDA) cleared the first blood test for the disorder. Fujirebio Diagnostics' Lumipulse measures the ratio of two proteins that correlate with the presence or absence of Alzheimer's. Previously, patients being screened for Alzheimer's were limited to more invasive options: a PET Scan or spinal tap.<br /> Lumipulse is intended for use in clinical settings with patients exhibiting signs of cognitive decline. At least in its current form, it isn't something the general population can ask for as a standard screening.<br /> The test works by measuring two proteins: pTau217 and β-amyloid 1-42. The blood test calculates their ratio, which cor [...]
The FDA has launched the generative AI tool, Elsa, agency-wide to help its employees with everything from clinical reviews to investigations. Sure, we're living in a time of widespread disinforma [...]
Picture this scenario: An Anthropic Skill scanner runs a full analysis of a Skill pulled from ClawHub or skills.sh. Its markdown instructions are clean, and no prompt injection is detected. No shell c [...]
Masimo, the medical technology company whose lawsuit led to the temporary sales pause of the Apple Watch Series 9 and Ultra 2, has sued the US Customs and Border Protection days after Apple released i [...]
Current and former members of the FDA told CNN about issues with the Elsa generative AI tool unveiled by the federal agency last month. Three employees said that in practice, Elsa has hallucinated non [...]